share_log

First Wave BioPharma Announced Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma Announced Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma 宣布扩大阿德鲁利酶的知识产权组合
Benzinga Real-time News ·  2023/01/25 07:08

First Wave BioPharma, Inc. (NASDAQ:FWBI) announced today the company has filed a U.S. Provisional Patent application involving composition of matter improvements designed to enhance adrulipase's delayed release profile. This filing adds to the growing intellectual property (IP) portfolio governing adrulipase, which includes patent applications governing adrulipase formulation and methods of use and the utilization of enteric formulations in the delivery of adrulipase.

First Wave BioPharma, Inc.(纳斯达克股票代码:FWBI)今天宣布,该公司已提交美国临时专利申请,涉及旨在增强adrulipase延迟发布状况的物质成分改进。该申请增加了管理阿德鲁利酶的知识产权(IP)组合,其中包括管理阿德鲁利酶配方和使用方法以及肠道制剂在阿德鲁利酶输送中的利用的专利申请。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发